Gary Nachman
Stock Analyst at Canaccord Genuity
(2.69)
# 2,817
Out of 4,468 analysts
472
Total ratings
47.6%
Success rate
1.1%
Average return
Main Sectors:
Stocks Rated by Gary Nachman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintained: Buy | $110 | $81.80 | +34.47% | 31 | Jun 24, 2026 | |
| ACHV Achieve Life Sciences | Reiterated: Buy | $13 | $6.40 | +103.13% | 8 | Jun 23, 2026 | |
| ABBV AbbVie | Reiterated: Buy | $265 → $273 | $261.07 | +4.57% | 43 | Jun 23, 2026 | |
| ADMA ADMA Biologics | Maintained: Buy | $18 | $8.95 | +101.12% | 8 | Jun 14, 2026 | |
| SRRK Scholar Rock Holding | Reiterated: Buy | $62 | $54.88 | +12.97% | 13 | Jun 2, 2026 | |
| AMGN Amgen | Maintained: Hold | $366 | $374.15 | -2.18% | 3 | May 1, 2026 | |
| PCRX Pacira BioSciences | Maintained: Hold | n/a | $25.39 | - | 48 | Oct 6, 2025 | |
| TSX: EPRX Eupraxia Pharmaceuticals Inc. | Maintained: Buy | $17.06 | $9.45 | +80.49% | 7 | Oct 2, 2025 | |
| VERU Veru Inc. | Maintained: Buy | $3 → $20 | $3.06 | +553.59% | 2 | Aug 13, 2025 | |
| INMB INmune Bio | Reiterated: Hold | n/a | $1.70 | - | 5 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $37 → $40 | $5.89 | +579.12% | 2 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $86 | $86.03 | n/a | 4 | Jun 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $7 | $4.18 | n/a | 18 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $243.47 | n/a | 48 | Jun 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $19 → $22 | $17.16 | n/a | 2 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $298 | $312.78 | n/a | 23 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $7 → $4 | $74.01 | n/a | 7 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $200 → $100 | $0.0001 | n/a | 8 | Mar 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 → $4 | $9.60 | n/a | 22 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $4 | $17.15 | n/a | 19 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 → $30 | $11.20 | n/a | 7 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $83 → $78 | $16.88 | n/a | 5 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $14 | $16.70 | n/a | 17 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $11.37 → $14.21 | $6.96 | n/a | 42 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $40 → $32 | $8.11 | n/a | 11 | Feb 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $10 | $34.64 | n/a | 7 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $3 | $38.72 | n/a | 11 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $60 → $35 | $0.00001 | n/a | 10 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $27 → $25 | $5.02 | n/a | 6 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $180 | $1.91 | n/a | 3 | Aug 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $13 → $12 | $17.93 | n/a | 5 | May 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $21 | $19.64 | n/a | 14 | May 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $9 → $3 | $0.0001 | n/a | 5 | Sep 5, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $80 | $44.74 | n/a | 1 | Sep 14, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $138 | $87.47 | n/a | 3 | Apr 27, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $9.5 → $14 | $4.33 | n/a | 2 | Mar 21, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $6.8 | $16.37 | n/a | 2 | Oct 9, 2013 |
Ionis Pharmaceuticals
Jun 24, 2026
Maintained: Buy
Price Target: $110
Current: $81.80
Upside: +34.47%
Achieve Life Sciences
Jun 23, 2026
Reiterated: Buy
Price Target: $13
Current: $6.40
Upside: +103.13%
AbbVie
Jun 23, 2026
Reiterated: Buy
Price Target: $265 → $273
Current: $261.07
Upside: +4.57%
ADMA Biologics
Jun 14, 2026
Maintained: Buy
Price Target: $18
Current: $8.95
Upside: +101.12%
Scholar Rock Holding
Jun 2, 2026
Reiterated: Buy
Price Target: $62
Current: $54.88
Upside: +12.97%
Amgen
May 1, 2026
Maintained: Hold
Price Target: $366
Current: $374.15
Upside: -2.18%
Pacira BioSciences
Oct 6, 2025
Maintained: Hold
Price Target: n/a
Current: $25.39
Upside: -
Eupraxia Pharmaceuticals Inc.
Oct 2, 2025
Maintained: Buy
Price Target: $17.06
Current: $9.45
Upside: +80.49%
Veru Inc.
Aug 13, 2025
Maintained: Buy
Price Target: $3 → $20
Current: $3.06
Upside: +553.59%
INmune Bio
Aug 4, 2025
Reiterated: Hold
Price Target: n/a
Current: $1.70
Upside: -
Jul 31, 2025
Maintained: Buy
Price Target: $37 → $40
Current: $5.89
Upside: +579.12%
Jun 20, 2025
Reiterated: Buy
Price Target: $86
Current: $86.03
Upside: n/a
Jun 17, 2025
Maintained: Buy
Price Target: $7
Current: $4.18
Upside: n/a
Jun 11, 2025
Maintained: Hold
Price Target: n/a
Current: $243.47
Upside: n/a
Feb 20, 2025
Maintained: Buy
Price Target: $19 → $22
Current: $17.16
Upside: n/a
Jan 15, 2025
Reiterated: Buy
Price Target: $298
Current: $312.78
Upside: n/a
Aug 19, 2024
Maintained: Buy
Price Target: $7 → $4
Current: $74.01
Upside: n/a
Mar 16, 2023
Rated: Buy
Price Target: $200 → $100
Current: $0.0001
Upside: n/a
Mar 8, 2023
Maintained: Buy
Price Target: $5 → $4
Current: $9.60
Upside: n/a
Mar 2, 2023
Rated: Hold
Price Target: $4
Current: $17.15
Upside: n/a
Mar 1, 2023
Maintained: Buy
Price Target: $35 → $30
Current: $11.20
Upside: n/a
Mar 1, 2023
Maintained: Buy
Price Target: $83 → $78
Current: $16.88
Upside: n/a
Feb 27, 2023
Rated: Hold
Price Target: $14
Current: $16.70
Upside: n/a
Feb 24, 2023
Maintained: Hold
Price Target: $11.37 → $14.21
Current: $6.96
Upside: n/a
Feb 22, 2023
Rated: Buy
Price Target: $40 → $32
Current: $8.11
Upside: n/a
Feb 8, 2023
Rated: Hold
Price Target: $10
Current: $34.64
Upside: n/a
Jan 9, 2023
Rated: Buy
Price Target: $3
Current: $38.72
Upside: n/a
Nov 10, 2022
Maintained: Buy
Price Target: $60 → $35
Current: $0.00001
Upside: n/a
Aug 11, 2022
Reiterated: Buy
Price Target: $27 → $25
Current: $5.02
Upside: n/a
Aug 2, 2021
Maintained: Buy
Price Target: $180
Current: $1.91
Upside: n/a
May 14, 2021
Rated: Buy
Price Target: $13 → $12
Current: $17.93
Upside: n/a
May 11, 2020
Maintained: Hold
Price Target: $21
Current: $19.64
Upside: n/a
Sep 5, 2019
Maintained: Buy
Price Target: $9 → $3
Current: $0.0001
Upside: n/a
Sep 14, 2017
Maintained: Buy
Price Target: $80
Current: $44.74
Upside: n/a
Apr 27, 2017
Reiterated: Buy
Price Target: $138
Current: $87.47
Upside: n/a
Mar 21, 2016
Initiated Coverage: Hold
Price Target: $9.5 → $14
Current: $4.33
Upside: n/a
Oct 9, 2013
Maintained: Hold
Price Target: $6.8
Current: $16.37
Upside: n/a